[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619061":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":68,"collaborators":33,"id":70,"slug":33,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":33,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":33,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":33,"overallStatus":50,"whyStopped":33,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"LY4515100 of Part A (SAD)","EXPERIMENTAL","Single-ascending doses of LY4515100 will be given orally",[13],"Drug: LY4515100 via SAD",{"label":15,"type":10,"description":16,"interventionNames":17},"LY4515100 of Part B (MAD)","Multiple-ascending doses of LY4515100 will be given orally",[18],"Drug: LY4515100 via MAD",{"label":20,"type":21,"description":22,"interventionNames":23},"Placebo Part A","PLACEBO_COMPARATOR","Placebo will be given orally",[13],{"label":25,"type":21,"description":22,"interventionNames":26},"Placebo Part B",[18],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","LY4515100 via SAD","given orally",[9,20],null,{"type":29,"name":35,"description":31,"armGroupLabels":36,"otherNames":33},"LY4515100 via MAD",[15,25],[38],{"name":39,"affiliation":5,"role":40},"Contact Lilly at 1-877-CTLILLY (1-877-285-4559) or","STUDY_DIRECTOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":33,"email":46},"There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","clinical_inquiry_hub@lilly.com",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Fortrea Clinical Research Unit","RECRUITING","Dallas","Texas","75247","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-96.80667,32.78306,{"lat":60,"lon":59},[63,65],{"name":33,"role":44,"phone":64,"phoneExt":33,"email":33},"866-429-3700",{"name":66,"role":67,"phone":33,"phoneExt":33,"email":33},"Gene Voskuhl","PRINCIPAL_INVESTIGATOR",{"type":69,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100619061",false,"NCT07339722","A Study of LY4515100 in Healthy Participants","A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants","Inclusion Criteria:\n\n* Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.\n* Have a body mass index within the range of 18.5 to 32.0 kilograms per square meter (kg\u002Fm\\^2) (inclusive).\n* Individuals of childbearing potential (IOCBP) are excluded from this trial.\n* Individuals not of childbearing potential (INOCBP) may participate in this trial.\n\nExclusion Criteria:\n\n* Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.\n* Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.\n* Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.\n* Participants with an estimated glomerular filtration rate \\\u003C90 mL\u002Fmin\u002F1.73 m2.\n* Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,\n* increases the risks associated with participating in the study\n* may confound ECG data analysis\n* Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.\n* Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.\n* Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)\n* Show evidence of\n* Human immunodeficiency virus (HIV) infection and\u002For positive human HIV antigen and\u002For antibodies\n* hepatitis C and\u002For positive hepatitis C antibody\n* hepatitis B and\u002For positive hepatitis B surface antigen.\n* Have liver disease.\n* Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.",true,"ALL","18 Years","65 Years",{"count":81,"type":82},40,"ESTIMATED","INTERVENTIONAL",[85],"PHASE1","The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.",[88],"Healthy","2026-06-19",{"date":91,"type":92},"2026-06-23","ACTUAL",{"date":94,"type":92},"2026-01-15",{"date":96,"type":82},"2026-07",{"name":5,"class":6},1]